Protalix Bio Presents Positive Phase 1 Data for PRX-115 in Uncontrolled Gout
• Protalix BioTherapeutics announced Phase 1 clinical trial data for PRX-115, a novel PEGylated uricase, showing promise in lowering urate levels.
• The study evaluated PRX-115 in participants with elevated urate, demonstrating prolonged plasma urate-lowering effects after a single intravenous dose.
• These findings were presented at the American College of Rheumatology (ACR) Convergence 2024, highlighting the potential of PRX-115 for uncontrolled gout.
• Protalix plans to make the poster presentation available on their website, offering further insights into the study's results and methodology.
© Copyright 2025. All Rights Reserved by MedPath